Asset Details
Do you wish to reserve the book?
Height and bone mineral content after inhaled corticosteroid use in the first 6 years of life
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Height and bone mineral content after inhaled corticosteroid use in the first 6 years of life
Do you wish to request the book?
Height and bone mineral content after inhaled corticosteroid use in the first 6 years of life
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Height and bone mineral content after inhaled corticosteroid use in the first 6 years of life
2022
Overview
BackgroundInfants and young children might be particularly susceptible to the potential side effects from inhaled corticosteroid (ICS) on height and bone mineral content (BMC), but this has rarely been studied in long-term prospective studies.MethodsChildren from two Copenhagen Prospective Studies on Asthma in Childhood cohorts were included. ICS use was registered prospectively from birth to age 6 and the cumulative dose was calculated. Primary outcomes were height and BMC from dual-energy X-ray absorptiometry (DXA) scans at age 6.ResultsAt age 6, a total of 930 children (84%) from the cohorts had a valid height measurement and 792 (71%) had a DXA scan. 291 children (31%) received a cumulated ICS dose equivalent to or above 10 weeks of standard treatment before age 6. We found an inverse association between ICS use and height, −0.26 cm (95% CI: −0.45 to −0.07) per 1 year standard treatment from 0 to 6 years of age, p=0.006. This effect was mainly driven by children with ongoing treatment between age 5 and 6 years (−0.31 cm (95% CI: −0.52 to −0.1), p=0.004), while there was no significant association in children who stopped treatment at least 1 year before age 6 (−0.09 cm (95% CI: −0.46 to 0.28), p=0.64). There was no association between ICS use and BMC at age 6.ConclusionsICS use in early childhood was associated with reduced height at age 6 years but only in children with continued treatment in the sixth year of life.
Publisher
BMJ Publishing Group Ltd and British Thoracic Society,BMJ Publishing Group LTD
